daclahep 60mg Tablet

Chronic hepatitis C virus (HCV) infection

The human body reacts differently to Daclahep 60mg Tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Daclahep 60mg Tablet are mentioned below:

Headache
Nausea
Unusual tiredness
Anemia
Insomnia
Dizziness
Shortness of breath
Irregular heartbeat
Chest pain
Fatigue Allergic reaction
Upset stomach
Trouble sleeping
Memory problems
Low blood sugar
Vomiting
Abdominal cramps
Swelling of the mouth, face, tongue, or throat

Take the dose of Daclahep 60mg Tablet as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you. This medicine is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. Daclahep 60mg Tablet can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole.

An antiviral medication, Daclahep 60mg Tablet, is used for the treatment of Hepatitis C virus (HCV) infection. It works by lowering the viral load from the blood; as a result, Infected individuals feel relief from the related symptoms of the chronic hepatitis C infection. Daclahep 60mg Tablet causes a decrease in serum RNA levels of HCV by stopping the function of the nonstructural protein 5A (NS5A) protein in the replication complex. The effect of this medicine can be easily seen within 2 hours after its oral administration.

It is advisable not to miss a dose. If you miss a scheduled dose of this medicine, contact your doctor immediately.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

1. Al-Nahari MM, Abbassi MM, Ebeid FS, Hassany M, El-Sayed MH, Farid SF. (2023). Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection. Antivir Ther. 25(2):101-110.

2. Gandhi Y, Eley T, Fura A, Li W, Bertz RJ, Garimella T. (2024). Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. Clin Pharmacokinet. 57(8):911-928..

3. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S; HALLMARK-DUAL Study Team. (2024). All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 384(9954):1597-605.

4. Schreiber J, McNally J, Chodavarapu K, Svarovskaia E, Moreno C. (2023). Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir. Hepatology. 64(3):983–5.

5. Smolders EJ, Colbers A, de Kanter C, Velthoven-Graafland K, Wolberink LT, van Ewijk-Beneken Kolmer N, et al. (2024). Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. Br J Clin Pharmacol. 83(10):2225–34.

6. US Food and Drug Administration. (2025). Highlights of prescribing information: Harvoni. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205834s017lbl.pdf.

7. Wei L, Zhang M, Xu M, Chuang WL, Lu W, Xie W, Jia Z, Gong G, Li Y, Bae SH, Yang YF, Xie Q, Lin S, Chen X, Niu J, Jia J, Garimella T, Torbeyns A, McPhee F, Treitel M, Yin PD, Mo L. (2024). A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. J Gastroenterol Hepatol. 31(11):1860-1867.

8. World Health Organization. Hepatitis C fact sheet. (2020). https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.